AXL and neoplasm: To further confirm the role of Axl pathway in EPC recruitment and tumour revascularization in vivo, HT‐29 tumour‐bearing mice received regorafenib or axitinib treatment for 7 days, followed by intragastric administration with R428 (Figure 9a).